FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993885251> ?p ?o ?g. }

• W1993885251 endingPage "666" @default.
• W1993885251 startingPage "658" @default.
• W1993885251 abstract "The complex network of etiological factors, signals and tissue responses involved in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) cannot be successfully targeted by a single therapeutic agent. Multimodal approaches to the therapy of CP/CPPS have been and are currently being tested, as in the frame of complex diagnostic‑therapeutic phenotypic approaches such as the urinary, psychosocial, organ‑specific, infection, neurological and muscle tenderness (UPOINTS) system. In this study, the effect of combination therapy on 914 patients diagnosed, phenotyped and treated in a single specialized prostatitis clinic was analyzed. Patients received α‑blockers, Serenoa repens (S. repens) extracts combined or not with supplements (lycopene and selenium) and, in the presence of documented or highly suspected infection, antibacterial agents. Combination treatment induced marked and significant improvements of National Institutes of Health Chronic Prostatitis Symptom Index (NIH‑CPSI) prostatitis symptom scores, International Index of Erectile Function (IIEF) sexual dysfunction scores, urinary peak flow rates and bladder voiding efficiency. These improvements, assessed after a 6‑month course of therapy, were sustained throughout a follow‑up period of 18 months. A clinically appreciable reduction of ≥6 points of the total NIH‑CPSI score was achieved in 77.5% of patients subjected to combination therapy for a period of 6 months. When the patients were divided in two cohorts, depending on the diagnosis of CP/CPPS [inflammatory (IIIa) vs. non‑inflammatory (IIIb) subtypes], significant improvements of all signs and symptoms of the syndrome were observed in both cohorts at the end of therapy. Intergroup comparison showed that patients affected by the IIIa sub‑category of CP/CPPS showed more severe signs and symptoms (NIH‑CPSI total, pain and quality of life impact scores, and Qmax) at baseline when compared with IIIb patients. However, the improvement of symptoms after therapy was significantly more pronounced in IIIa patients when compared with IIIb patients. In contrast to current opinion, the evidence emerging from the present investigation suggests that the inflammatory and non‑inflammatory sub‑categories of CP/CPPS may represent two distinct pathological conditions or, alternatively, two different stages of the same condition. In conclusion, a simple protocol based on α‑blockers, S. repens extracts and supplements and antibacterial agents, targeting the urinary, organ specific and infection domains of UPOINTS, may induce a clinically appreciable improvement of the signs and symptoms of CP/CPPS in a considerable percentage of patients. In patients not responding sufficiently to such therapy, second‑line agents (antidepressants, anxiolytics, muscle relaxants, 5‑phosphodiesterase inhibitors and others) may be administered in order to achieve a satisfactory therapeutic response." @default.
• W1993885251 created "2016-06-24" @default.
• W1993885251 creator A5002741156 @default.
• W1993885251 creator A5012976194 @default.
• W1993885251 creator A5045750331 @default.
• W1993885251 creator A5048212753 @default.
• W1993885251 creator A5055353201 @default.
• W1993885251 date "2014-12-19" @default.
• W1993885251 modified "2023-10-14" @default.
• W1993885251 title "Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients" @default.
• W1993885251 cites W1592602394 @default.
• W1993885251 cites W1968481120 @default.
• W1993885251 cites W1969508692 @default.
• W1993885251 cites W1978505438 @default.
• W1993885251 cites W1979491803 @default.
• W1993885251 cites W1989652170 @default.
• W1993885251 cites W1991352462 @default.
• W1993885251 cites W1997517088 @default.
• W1993885251 cites W2007099638 @default.
• W1993885251 cites W2014224471 @default.
• W1993885251 cites W2029270641 @default.
• W1993885251 cites W2033224815 @default.
• W1993885251 cites W2038464024 @default.
• W1993885251 cites W2045868653 @default.
• W1993885251 cites W2056406352 @default.
• W1993885251 cites W2065642192 @default.
• W1993885251 cites W2091751443 @default.
• W1993885251 cites W2093948837 @default.
• W1993885251 cites W2111553467 @default.
• W1993885251 cites W2120349925 @default.
• W1993885251 cites W2127461426 @default.
• W1993885251 cites W2128950406 @default.
• W1993885251 cites W2142758888 @default.
• W1993885251 cites W2142820536 @default.
• W1993885251 cites W2152331728 @default.
• W1993885251 cites W2152425345 @default.
• W1993885251 cites W2155274553 @default.
• W1993885251 cites W2156895167 @default.
• W1993885251 cites W2163752799 @default.
• W1993885251 doi "https://doi.org/10.3892/etm.2014.2152" @default.
• W1993885251 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4316954" @default.
• W1993885251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25667610" @default.
• W1993885251 hasPublicationYear "2014" @default.
• W1993885251 type Work @default.
• W1993885251 sameAs 1993885251 @default.
• W1993885251 citedByCount "47" @default.
• W1993885251 countsByYear W19938852512015 @default.
• W1993885251 countsByYear W19938852512016 @default.
• W1993885251 countsByYear W19938852512017 @default.
• W1993885251 countsByYear W19938852512018 @default.
• W1993885251 countsByYear W19938852512019 @default.
• W1993885251 countsByYear W19938852512020 @default.
• W1993885251 countsByYear W19938852512021 @default.
• W1993885251 countsByYear W19938852512022 @default.
• W1993885251 countsByYear W19938852512023 @default.
• W1993885251 crossrefType "journal-article" @default.
• W1993885251 hasAuthorship W1993885251A5002741156 @default.
• W1993885251 hasAuthorship W1993885251A5012976194 @default.
• W1993885251 hasAuthorship W1993885251A5045750331 @default.
• W1993885251 hasAuthorship W1993885251A5048212753 @default.
• W1993885251 hasAuthorship W1993885251A5055353201 @default.
• W1993885251 hasBestOaLocation W19938852511 @default.
• W1993885251 hasConcept C121608353 @default.
• W1993885251 hasConcept C126322002 @default.
• W1993885251 hasConcept C126894567 @default.
• W1993885251 hasConcept C137627325 @default.
• W1993885251 hasConcept C141071460 @default.
• W1993885251 hasConcept C2776235491 @default.
• W1993885251 hasConcept C2776362571 @default.
• W1993885251 hasConcept C2778508898 @default.
• W1993885251 hasConcept C2779478474 @default.
• W1993885251 hasConcept C2779529836 @default.
• W1993885251 hasConcept C2779929075 @default.
• W1993885251 hasConcept C2780136519 @default.
• W1993885251 hasConcept C2780524745 @default.
• W1993885251 hasConcept C4441509 @default.
• W1993885251 hasConcept C71924100 @default.
• W1993885251 hasConcept C77411442 @default.
• W1993885251 hasConceptScore W1993885251C121608353 @default.
• W1993885251 hasConceptScore W1993885251C126322002 @default.
• W1993885251 hasConceptScore W1993885251C126894567 @default.
• W1993885251 hasConceptScore W1993885251C137627325 @default.
• W1993885251 hasConceptScore W1993885251C141071460 @default.
• W1993885251 hasConceptScore W1993885251C2776235491 @default.
• W1993885251 hasConceptScore W1993885251C2776362571 @default.
• W1993885251 hasConceptScore W1993885251C2778508898 @default.
• W1993885251 hasConceptScore W1993885251C2779478474 @default.
• W1993885251 hasConceptScore W1993885251C2779529836 @default.
• W1993885251 hasConceptScore W1993885251C2779929075 @default.
• W1993885251 hasConceptScore W1993885251C2780136519 @default.
• W1993885251 hasConceptScore W1993885251C2780524745 @default.
• W1993885251 hasConceptScore W1993885251C4441509 @default.
• W1993885251 hasConceptScore W1993885251C71924100 @default.
• W1993885251 hasConceptScore W1993885251C77411442 @default.
• W1993885251 hasIssue "3" @default.
• W1993885251 hasLocation W19938852511 @default.
• W1993885251 hasLocation W19938852512 @default.
• W1993885251 hasLocation W19938852513 @default.

• next